Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...
Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback